RxDoctor Payments Data

Liana Spano-Brennan, DO

Cardiovascular Disease · Berkeley Heights, NJNPI 1740466861

Payments from drug & device makers

$273in general payments, 2019–2025

Across 4 payments — averaging $68.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$146
  • Impulse Dynamics (USA) Inc.$116
  • Johnson & Johnson$11

What the payments were for

  • Food & beverage$273100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$273 in reported general payments places this provider in the 10th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$336,104
Medicare patients
1,382
Services billed
4,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban465$664,560
XareltoRivaroxaban320$392,196
EntrestoSacubitril/Valsartan100$139,017
BrilintaTicagrelor16$17,212
Metoprolol Succinate949$14,818
Praluent PenAlirocumab11$11,117
Repatha SureclickEvolocumab11$10,197
Atorvastatin Calcium637$8,199
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,422
Rosuvastatin Calcium309$4,437
Diltiazem 24hr Er (Cd)Diltiazem Hcl122$4,379
Amlodipine Besylate373$3,126
Ezetimibe137$2,854
Losartan Potassium228$2,339
Valsartan72$2,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$11$392,196320 claims
NovartisEntresto$146$139,017100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Berkeley Heights

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →